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Lowe syndrome, which is characterized by defects in the central nervous system, eyes and kidneys, is
caused by mutation of the phosphoinositide 5-phosphatase OCRL1. The mechanisms by which loss of
OCRL1 leads to the phenotypic manifestations of Lowe syndrome are currently unclear, in part, owing to
the lack of an animal model that recapitulates the disease phenotype. Here, we describe a zebraﬁsh model
for Lowe syndrome using stable and transient suppression of OCRL1 expression. Deﬁciency of OCRL1,
which is enriched in the brain, leads to neurological defects similar to those reported in Lowe syndrome
patients, namely increased susceptibility to heat-induced seizures and cystic brain lesions. In OCRL1-
deﬁcient embryos, Akt signalling is reduced and there is both increased apoptosis and reduced proliferation,
most strikingly in the neural tissue. Rescue experiments indicate that catalytic activity and binding to the ves-
icle coat protein clathrin are essential for OCRL1 function in these processes. Our results indicate a novel
role for OCRL1 in neural development, and support a model whereby dysregulation of phosphoinositide
metabolism and clathrin-mediated membrane trafﬁc leads to the neurological symptoms of Lowe syndrome.
INTRODUCTION
Oculocerebrorenal syndrome of Lowe is an X-linked disorder
with the hallmark symptoms of congenital cataracts, mental
retardation and proximal renal tubulopathy (1,2). Lowe syn-
drome is caused by mutation of the gene encoding OCRL1,
a type II inositol polyphosphate 5-phosphatase which prefer-
entially hydrolyses PtdIns(4,5)P2, although it also displays
activity towards PtdIns(3,4,5)P3 (3,4). Mutation of OCRL1
also causes Dent disease (in  20% of cases), which primarily
affects the kidneys with little or none of the associated ocular
and neurological symptoms (5,6).
OCRL1 is a multi-domain protein with an N-terminal PH
domain, a central 5-phosphatase domain and C-terminal
ASH and catalytically inactive RhoGAP-like domains
(4,7,8). OCRL1 is localized to the trans-Golgi network, early
endosomes, lamellipodia and clathrin-coated membrane-
trafﬁcking intermediates (4). It has also recently been loca-
lized to cellular junctions and the intercellular bridge during
cytokinesis (9,10). Targeting at these various locations is
mediated through binding with Rab GTPases (11,12), although
interaction with other proteins helps localize the protein to
particular membrane domains. Enrichment in clathrin-coated
trafﬁcking intermediates is dependent upon binding to compo-
nents of the clathrin machinery (clathrin heavy chain and the
a-adaptin subunit of AP2) (8,13–15), while interaction with
the small GTPases Rac1 and Cdc42 likely helps OCRL1 asso-
ciate with the actin cytoskeleton (7,16,17). OCRL1 also binds
the ARF1 and ARF6 GTPases (18), the signalling adaptor
protein APPL1 (7,19) and the endosomal proteins IPIP27A
and B (or Ses1 and 2) that were recently shown to participate
in endocytic recycling (20,21).
Functional studies using tissue culture cells have revealed a
role for OCRL1 in endosomal trafﬁcking (14,22,23) consistent
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chinery. Analysis of Lowe syndrome patient cells has also
revealed defective cell adhesion and migration upon loss of
OCRL1 function (9,24). These may correspond to a direct
effect upon the actin cytoskeleton or could arise through
altered trafﬁcking of the machinery required for these pro-
cesses. A role for OCRL1 in cytokinesis has also recently
been discovered, where OCRL1 would appear to act directly
given its localization to the intercellular bridge prior to abscis-
sion (10,25). OCRL1 likely regulates these processes through
PtdIns(4,5)P2 and PtdInd(3,4,5)P3 hydrolysis, which in turn
controls membrane and actin dynamics at speciﬁc subcellular
locations.
Vertebrates express a second 5-phosphatase that is closely
related to OCRL1 called INPP5B (26,27). INPP5B shares
the same domain organization and has a similar substrate pref-
erence to OCRL1, and is also localized to the Golgi apparatus
and endosomes (7,8,27–29). INPP5B binds to many of the
OCRL1-binding partners, although there are some differences,
most notably in clathrin binding, which is lacking in INPP5B
(7,29). It appears that OCRL1 and INPP5B share overlapping
functionality, since knockout of OCRL1 or INPP5B in mice
gives no phenotype, or in the case of INPP5B, a very mild
one restricted to the testis, while double-knockout of
OCRL1 and INPP5B results in early embryonic lethality
(30,31). This suggests that mouse INPP5B can fully compen-
sate for OCRL1, while in humans, compensation is only
partial. In support of this hypothesis, a mouse model in
which human INPP5B is expressed in a background lacking
murine OCRL1 and INPP5B exhibits a renal tubulopathy rem-
iniscent to that seen in Lowe syndrome patients (32). The
ability of INPP5B to compensate for loss of OCRL1 likely
explains the tissue-speciﬁc nature of Lowe syndrome,
despite the near-ubiquitous expression of OCRL1 in human
tissues.
Despite progress in the understanding of the cell biology of
OCRL1, how loss of the protein leads to the pathological
changes seen in Lowe syndrome and Dent disease remains
unclear. It has been proposed that defective trafﬁcking of the
multi-ligand receptor megalin accounts for the renal symptoms
observed in these disorders, but this remains to be demon-
strated (4,33). The basis for the neurological symptoms of
Lowe syndrome is even less well understood. These include
mental retardation, neonatal hypotonia, stereotypical behav-
iour and an increased susceptibility to seizures (2). Magnetic
resonance imaging (MRI) indicates cystic lesions in the
white matter of Lowe syndrome patients, often in the periven-
tricular region (2,34–36). It is interesting to note that OCRL1
is highly expressed in brain, and that only the longer splice
variant, isoform a, is present in this tissue, while other
tissues express both isoforms a and b (37,38). OCRL1
isoform a exhibits higher afﬁnity clathrin-binding and
increased association with clathrin-trafﬁcking intermediates
(15), suggesting an important role for OCRL1 in clathrin-
mediated trafﬁcking in the brain. This hypothesis remains to
be tested.
In this study, we describe a zebraﬁsh model for Lowe syn-
drome. OCRL1-deﬁcient zebraﬁsh embryos are more suscep-
tible to seizures and adults exhibit cystic brain lesions,
recapitulating the symptoms of Lowe syndrome. Loss of
OCRL1 impairs cell survival and reduces cell proliferation
within the developing neurological tissue, indicating a novel
role for OCRL1 in embryonic brain development. Both cata-
lytic activity and clathrin-binding are required for OCRL1
function during this process, suggesting that dysregulation of
phosphoinositide metabolism and clathrin-mediated trafﬁck-
ing are responsible for the neurological symptoms of Lowe
syndrome.
RESULTS
Conservation of OCRL1 and INPP5B in vertebrates
Genes encoding the paralogues OCRL1 and INPP5B are
present in all vertebrates, including the zebraﬁsh Danio
rerio, while ‘lower’ metazoans such as Drosophila melanoga-
ster and Caenorhabditis elegans express only a single ortholo-
gue of these proteins (Supplementary Material, Fig. S1).
Zebraﬁsh has a single gene for each of the phosphatases,
with OCRL1 mapping to chromosome 14 and INPP5B to
chromosome 16. There is a high degree of sequence conserva-
tion between zebraﬁsh OCRL1 and INPP5B and their human
orthologues (Fig. 1A). The functional domains of both pro-
teins are also well conserved, as are the interaction motifs
for the known binding partners of these proteins, including
the two clathrin boxes present in the PH and RhoGAP-like
domains of OCRL1 (Fig. 1A and Supplementary Material,
Fig. S2).
Zebraﬁsh OCRL1 is localized to the Golgi apparatus
and early endosomes
To determine the subcellular localization of zebraﬁsh OCRL1,
a GFP-tagged version was expressed in cultured zebraﬁsh
ﬁbroblasts and immunoﬂuorescence microscopy performed.
GFP–OCRL1 ﬂuorescence coincided with staining of the
Golgi marker golgin-84 and the early endosome marker
EEA1 (Fig. 1B). We also observed colocalization with
co-transfected mCherry-tagged clathrin light chain (CLC) in
cytoplasmic puncta, consistent with the presence of zebraﬁsh
OCRL1 in clathrin-coated trafﬁcking intermediates
(Fig. 1B). Isoform b was also present at the Golgi apparatus
and endosomes, but the cytoplasmic puncta were less appar-
ent, as seen with the human protein, suggesting reduced asso-
ciation with clathrin structures. This was conﬁrmed by
quantitation, which revealed that 37% of clathrin puncta con-
tained OCRL1 isoform a while only 13% were positive for
isoform b. These results indicate that zebraﬁsh OCRL1 exhi-
bits a similar subcellular distribution to the human protein.
Expression proﬁle and splicing of zebraﬁsh OCRL1
We next analysed the expression of zebraﬁsh OCRL1 in adult
tissues by reverse transcriptase-polymerase chain reaction
(RT-PCR) and western blotting. OCRL1 mRNA was detected
in all adult tissues examined, indicating its widespread expres-
sion (Fig. 1C). Using primers to discriminate between OCRL1
splice isoforms, we found that isoform b is the predominant
form in most tissues, while in heart and skeletal muscle,
isoform a is more abundant and in brain it is the only splice
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seen with human OCRL1 (38). As shown in Fig. 1D,
OCRL1 was most abundant at the protein level in the brain,
similar to that seen with the mouse protein (30). We could
also detect OCRL1 in other tissues, although its abundance
in liver and kidney appeared low (Fig. 1D).
The expression of OCRL1 during embryogenesis was also
analysed. RT–PCR indicated the presence of maternal
OCRL1 mRNA at the onset of development, with zygotic ex-
pression evident throughout subsequent developmental stages
(Fig. 2A). Western blotting conﬁrmed the expression of
OCRL1 protein throughout the early stages of development
Figure 1. OCRL1 domain organization, subcellular localization, and tissue-speciﬁc splicing and expression are conserved in zebraﬁsh. (A) Schematic view of
human and zebraﬁsh OCRL1 and Inpp5 showing the predicted PH, 5-phosphatase, ASH and RhoGAP-like domains. The table indicates amino acid identity
between the proteins. (B) Immunoﬂuorescence microscopy of zebraﬁsh AB9 or PAC2 ﬁbroblast cells expressing GFP-tagged OCRL1 isoform a or b (green)
with or without mCherry-tagged clathrin light chain (CLC) and labelled with antibodies to Golgin84 or EEA1 (red). Arrows indicate colocalization of
OCRL1a with EEA1 or mCherry-clathrin light chain. Scale bar, 10 mm. (C) RT–PCR of adult zebraﬁsh tissues using primers against OCRL1 isoform a and
b, or the control ZFPL1. B, brain; F, ﬁn; G, gill; H, heart; I, intestine; K, kidney; L, liver; M, muscle; S, skin. (D) Western blot of zebraﬁsh adult tissues
using the indicated antibodies. K, kidney; L, liver; S, skin; B, brain; H, heart; G, gill. Ponceau staining of the membrane shows similar loading per lane.
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OCRL1 expression is ubiquitous, with enrichment seen in the
neural tissue at 1 and 3 days post-fertilization (dpf) (Fig. 2C).
This staining is speciﬁc: we observed identical patterns with
two independent probes and there was no staining with the
sense control probes at all stages analysed (Fig. 2C and data
not shown). Analysis of cryosections indicates that OCRL1 is
widely expressed throughout the neural tissue, with no particu-
lar enrichment in any region of the brain (Fig. 2D).
OCRL1-deﬁcient embryos have elevated levels of
PtdIns(4,5)P2
To generate a vertebrate model for Lowe syndrome in which
we could analyse both embryogenesis and later stages of
life, we obtained transgenic zebraﬁsh containing a retroviral
insertion in the OCRL1 promoter (Fig. 3A, left). Genotyping
conﬁrmed the presence of the insertion upstream of the
OCRL1 start codon (Fig. 3A, right). Western blotting of
homozygous mutant embryos indicated that protein expression
was reduced by approximately 70% in this line, herein referred
to as OCRL12/2 (Fig. 3B, top). The speciﬁcity of blotting
was conﬁrmed by injecting an ATG-blocking morpholino
(MO) into wild-type (WT) embryos, which also signiﬁcantly
reduced OCRL1 protein levels (Fig. 3B, bottom). Previous
analysis of Lowe syndrome patients’ cells revealed an increase
in PtdIns(4,5)P2 levels by 1.9–2.1-fold when compared with
controls, consistent with the loss of OCRL1 5-phosphatase ac-
tivity in Lowe syndrome (39,40). We therefore wanted to
determine whether the OCRL1 mutant embryos displayed ele-
vated levels of PtdIns(4,5)P2. For this purpose, we developed a
metabolic labelling protocol allowing the measurement of
phosphoinositide lipids in zebraﬁsh embryos at 48 hpf.
Using this method, we could show that OCRL1 mutant
embryos have a 1.8-fold increase in PtdIns(4,5)P2, comparable
with that seen in Lowe syndrome patients (Fig. 3C).
OCRL1-deﬁcient embryos have increased susceptibility to
seizures
Lowe syndrome patients are prone to generalized motor sei-
zures, and are nine times more likely to experience febrile
convulsions compared with healthy subjects (2,34). We there-
fore investigated whether the OCRL1-deﬁcient mutant
embryos display a similar susceptibility to heat-induced sei-
zures. Electrophysiological recordings taken from the fore-
brain of OCRL1 mutant and control embryos revealed that
while the temperature for seizure initiation is the same for
control and mutant embryos, the OCRL1 mutants have signiﬁ-
cantly longer seizure duration than the control (Fig. 4A, C and
D). The increased activity in the mutants can also be seen in a
power analysis of seizure amplitude versus frequency
(Fig. 4B). We failed to observe spontaneous seizure activity
over the 45 min duration of the electrophysiological record-
ings. However, casual inspection of freely behaving juvenile
and adult mutants indicates that they occasionally undergo un-
controlled twitching followed by rigor before recovering,
Figure 2. Developmental expression of zebraﬁsh OCRL1. (A) RT–PCR of cDNA prepared at different embryonic developmental time points using primers
against total OCRL1 and the control ZFPL1. (B) Western blotting of protein extracts from zebraﬁsh embryos at different developmental time points with
the indicated antibodies. (C) Images of whole-mount ISH with OCRL1 probe antisense and sense (control) at the developmental time-points indicated. (D) Trans-
verse (T), sagittal (S) and coronal (C) cryosections of whole-mount ISH with OCRL1 probe at the times of development indicated.
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during their lifetime.
OCRL1-deﬁcient zebraﬁsh have reduced survival and
growth
Ocular and neurological symptoms of Lowe syndrome are
present at birth, indicating early developmental defects in
humans (2). The increased susceptibility of OCRL1 mutant
embryos to seizures indicates the early appearance of neuro-
logical abnormalities in this model. We therefore assessed via-
bility of the OCRL1 mutant zebraﬁsh. Strikingly, we observed
a 60% mortality rate for the mutant in the ﬁrst 3 weeks of life,
compared with only 20% for the WT controls (Supplementary
Material,Fig.S3).This3-foldincreaseinmortalityisconsistent
withthedevelopmentaldefectsattributabletoOCRLdeﬁciency
leadingtoreducedviability.Lowesyndromeischaracterizedby
growth retardation in the early years of life. We therefore ana-
lysed growth in the OCRL1 mutants. As shown in Supplemen-
tary Material, Fig. S4, juvenile OCRL1 mutant zebraﬁsh are
reduced in length when compared with WT controls at both 1
and 2 months. This is consistent with a growth defect similar
to that seen in human patients.
Cystic brain lesions are present in OCRL1-deﬁcient
zebraﬁsh
BrainabnormalitieshavebeenreportedinMRIimagesofLowe
syndrome patients (2,34–36). These typically correspond to
periventricular cysts and white matter changes consistent with
gliosis. We therefore performed micro-MRI (mMRI) imaging
to determine whether similar changes would be present in the
Figure 3. A zebraﬁsh mutant deﬁcient in OCRL1 has elevated PtdIns(4,5)P2 levels. (A) Left: Schematic diagram showing the location of the retroviral insertion
upstream of the OCRL1 start codon. Primers used to amplify genomic DNA from zebraﬁsh embryos are indicated. Right: Agarose gel analysis of DNA ampliﬁed
from OCRL12/2, +/2 and +/+ embryos using the indicated primer pairs. (B) Western blotting of WT, OCRL12/2 and OCRL1+/+ zebraﬁsh embryos at
2 dpf, or embryos injected with a translation-blocking OCRL1 morpholino (ATGMO). Representative blots and quantitation are shown. Results are expressed as
the mean + SEM from ﬁve experiments. (C) Quantitation of PtdIns(4,5)P2 levels in WT and OCRL12/2 embryos at 2 dpf. Results are expressed as the mean +
SEM from six experiments.
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lysis as embryos and juveniles are not amenable to MRI. We
could detect white matter lesions in all eight mutant ﬁsh ana-
lysed, while none were detected in eight WT controls
(Fig. 5A, left). The lesions were always in the periventricular
region,andappearedtobeﬁlledwithcerebrospinalﬂuidaccord-
ing to MRI T2 relaxation times (Supplementary Material,
Fig. S5). The nature of the lesions was further investigated
using immunohistochemistry. We observed strong glial ﬁbril-
lary acid protein (GFAP) staining inthe lesions when compared
with elsewhere in the brain, consistent with increased numbers
of astrocytes in these regions, indicative of gliosis (Fig. 5B,
right). In contrast, GFAP staining was largely absent from the
periventricularregionofcontrolanimals.OCRL1-deﬁcientzeb-
raﬁsh therefore develop white matter abnormalities similar to
those reported in Lowe syndrome patients.
OCRL1 deﬁciency impairs neural development during
embryogenesis
The presence of neurological abnormalities, namely increased
seizure susceptibility, in OCRL1-deﬁcient zebraﬁsh embryos
suggests that OCRL1 may play a role in neural development
during embryogenesis. We therefore analysed the OCRL1-
deﬁcient mutant embryos in more detail. The morphology of
mutant embryos was assessed at different stages of develop-
ment. The most striking phenotype is the reduction in the
size of the brain and eyes of OCRL1 mutant embryos,
which is most obvious at 1 dpf (Fig. 6A). The reduced size
of these tissues does not simply reﬂect smaller overall size
of the mutant embryos, as this was the same as WT
embryos at 1 dpf (data not shown). The midbrain–hindbrain
boundary is less deﬁned when compared with controls at
this stage, and the eyes are underdeveloped. There are
however no obvious cataracts or opacities in the lens of
mutant embryos. The mutant embryos also have a reduction
in pigmentation that is also seen at later stages (Supplementary
Material, Fig. S4A and data not shown). To better assess the
reduction in brain size in the mutants, we performed confocal
microscopy of the head region of whole-mount embryos, and
histology on transverse sections taken through different
regions of the head. Both approaches revealed a signiﬁcant re-
duction in neural tissue in the fore-, mid- and hindbrain
regions of mutants at 1 dpf (Fig. 6B and C). Importantly,
Figure 4. Electrographic seizure activity in OCRL1 mutant zebraﬁsh. (A) Representative recoding taken from the forebrain of parental OCRL1
+/+ and
OCRL1
2/2 mutant zebraﬁsh embryos at 6 dpf. (B) Plot of amplitude versus frequency of recordings taken from OCRL1
+/+ and OCRL1
2/2 embryos. (C,D)
Plot of average temperature at onset of seizure (C) and duration of seizure activity (D) in OCRL1
+/+ and OCRL1
2/2 embryos. Data are presented as
mean + SEM (n ¼ 23–30). ∗P , 0.001.
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Embryoswereconﬁrmedtobeatthesamestageofdevelopment
according to somite number (Supplementary Material, Fig. S7).
Moreover, time-lapse microscopy showed that the OCRL1-
deﬁcient embryos progress through the ﬁrst 18 h of embryo-
genesis at the same rate as controls, as assessed by gross
morphology, arguing against a general developmental delay in
the mutants (Supplementary Material, Fig. S6 and Movie S1).
The morphological changes described above are speciﬁc to
loss of OCRL1. Firstly, they are phenocopied by injection of
an ATG MO that efﬁciently knocks down OCRL1 expression
(Figs 3B and 6A). For the MO injections, we used p53-deﬁcient
embryos tominimize off-target effects (41). Secondly, the mor-
phological differences seen in both the mutant and morphant
embryos are rescued, at least partially, by re-expression of
WT GFP-tagged zebraﬁsh OCRL1 (Fig. 6D). We do not
observe changes in the patterning or levels of expression of
various markers of brain region speciﬁcation analysed at
1 dpf, including foxG1 (telenecephalon), otx3 (midbrain),
hoxb1a (rhombomere 4) and hoxb4 (rhombomeres 6 and 7)
(Supplementary Material, Fig. S7). With pax2.1 (optic stalk,
MHB and otic vesicle), we observed a reduction in length
between the optic stalk, MHB and otic vesicle, consistent with
a reduction in brain size at this point in development (Supple-
mentary Material, Fig. S7). Similarly, krox20 labelling displays
a similar pattern between mutant and control embryos, but with
reducedseparation between rhombomeres 3and 5inthe mutant
consistent with a reduced brain size.
OCRL1 is required for Akt signalling and cell survival and
proliferation during embryogenesis
The impaired development of the brain in OCRL1 mutant
and morphant embryos is consistent with the high level of
OCRL1 expression in this tissue. OCRL1 has previously
been implicated in several cellular processes including mem-
brane trafﬁc and intracellular signalling, both of which are
important for neural development. To determine whether de-
ﬁciency of OCRL1 affects intracellular signalling during em-
bryogenesis, we determined the activation status of two
major signalling pathways, namely the MAPK and Akt path-
ways, using phospho-speciﬁc antibodies. There were compar-
able levels of phospho-ERK in mutant and WT embryos,
indicating that MAPK signalling was unaffected by OCRL1
deﬁciency (Fig. 7A). In contrast, Akt signalling was notice-
ably attenuated in the OCRL1 mutant, indicated by a reduc-
tion in phospho-Akt reactivity. Interestingly, total Akt levels
also appeared reduced in the OCRL1 mutants, suggesting a
defect in signalling pathways upstream of Akt expression.
The reduction in phospho- and total Akt levels were rescued
by expression of GFP–OCRL1, indicating the speciﬁcity of
these effects (Fig. 7A). The Akt pathway is most commonly
associated with cell survival, so we decided to investigate
whether apoptosis may be increased in the OCRL1 mutant
beyond the naturally occurring level seen in embryogenesis.
Using both acridine orange labelling of live embryos and
TUNEL staining of ﬁxed embryos, we found a signiﬁcant
Figure 5. White matter lesions in OCRL1 mutant zebraﬁsh. (A) Transverse relaxation (T2)-weighted MRI images of the brains of WT and OCRL12/2 adult
zebraﬁsh. Sagittal images indicate the presence of a white matter anomaly (white arrow in insert) in OCRL2/2, which was not seen in WT. Coronal images
show the presence of lesions adjacent to the ventricles (white arrow in insert). Immunohistochemistry was carried out on the same samples used for MRI.A
higher number of GFAP-positive astrocytes are present in the periventricular lesion suggesting increased gliosis. (B) Examples of GFAP staining of WT and
OCRL12/2 brain regions. Note the increased numbers of astrocytes concentrated in regions that correspond to periventricular lesions of OCRL12/2 embryos.
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plementary Material, Fig. S8). Apoptotic cells were present
throughout the embryo, indicating a global defect in cell sur-
vival. Importantly, a comparable increase in apoptosis was
observed in OCRL1 MO-injected p53-deﬁcient embryos (Sup-
plementary Material, Fig. S8). The increased apoptosis seen in
both mutant and morphants could be rescued by re-expression
ofGFP-taggedOCRL1,indicatingthattheseeffectsarespeciﬁc
to loss of OCRL1 (Fig. 7B).
Proliferation was also assessed in the OCRL1 mutant
embryos using phospho-histone H3 (PH3) as a marker for
mitotic cells. Proliferating cells were present throughout WT
embryos but most evident in the periventricular region
where the bulk of neurogenesis takes place (Fig 7C, arrows
and Supplementary Material, Movie S2). In OCRL1 mutant
embryos, there was a clear reduction in PH3 staining, indicat-
ing reduced levels of proliferation. The striking loss of PH3
staining in the periventricular region is consistent with
impaired neurogenesis in the mutant. As observed for morph-
ology, Akt activation and apoptosis, the reduced levels of pro-
liferation observed in the mutant were rescued by
re-expression of GFP-tagged OCRL1 (Fig. 7C). Together,
these results indicate an important role for OCRL1 in Akt sig-
nalling, cell survival and proliferation during embryogenesis.
Figure 6. Impaired development of the brain and eyes in OCRL1-deﬁcient embryos. (A) Representative bright ﬁeld images of 26 hpf WT and OCRL12/2
uninjected embryos, or WT embryos injected with either mock or ATGMO morpholino. (B) Confocal slices of 1 dpf WT and OCRL12/2 embryos stained
with DRAQ5 to label the nuclei. The overlay is false-coloured with WT staining in blue and OCRL12/2 in red. (C) Representative H&E-stained cryosections
from the forebrain (top) or R5 hindbrain region (bottom) of 1 dpf WT and OCRL12/2 embryos. Arrows indicate the reduction in size of these regions in the
OCRL mutant. Quantitation of neural tissue cross-sectional area of forebrain sections. Data are expressed as the mean + SEM (n ¼ 10). (D) Quantitation of
morphological phenotype. Results are expressed as the mean + SEM (n ¼ 63–501 embryos from 4 to 13 experiments). The WT morphology is normal. Dys-
morphic describes embryos with a smaller head and eyes and loss of deﬁned MHB. This phenotype is seen in both OCRL1 morphant and mutant embryos. Other
describes embryos with more severe anatomical defects not restricted to the brain and eyes that may arise from high-level over-expression of OCRL1a.
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for OCRL1 function in vivo
To determine the cellular mechanisms underlying the defects,
we observe in OCRL1 mutant and morphant embryos, rescue
experiments were performed using constructs with point muta-
tions that abrogate catalytic activity (D480A) or binding to the
vesiclecoatproteinclathrin (△LIDLE).Morphology,apoptosis
and proliferation were scored to determine the ability of each
construct to rescue these phenotypes. Importantly, expression
levels of the various constructs were comparable as assessed
by GFP ﬂuorescence. Expression of the catalytically inactive
D480A mutant failed to rescue mutant morphology, apoptosis
or proliferation, indicating that 5-phosphatase activity is essen-
tial for OCRL1 function in vivo (Fig. 8A–C). Interestingly, ex-
pression of this construct led to a more severe morphological
defectthanthatseeninthemutantalone,withagreaterreduction
in the size of the brain (Fig. 8A). Moreover, we observed
enhanced apoptosis in embryos expressing the D480A mutant
(Fig. 8B). This was particularly striking in the head, suggesting
increasedapoptosiswithintheneuraltissue.Wealsoobserveda
greaterreductionincellproliferationinmutantembryosexpres-
sing the D480A mutant (Fig. 8C). These results conﬁrm the
functional importance of OCRL1 5-phosphatase activity
during embryonic development.
OCRL1 interacts with clathrin through two binding sites,
LIDIA(LIDIDinzebraﬁsh)andLIDLE,whicharefoundonﬂex-
ibleloopsprotrudingfromthePHandRhoGAP-likedomains,re-
spectively (8,15). We have previously shown that the second site
ismostimportantforlocalizationofOCRL1toclathrintrafﬁcking
intermediatesincells(15).DifferentialsplicingofOCRL1occurs
next to this site, which alters its ability to interact with clathrin,
such that splice isoform a binds better than isoform b, and as a
resultismoreenrichedinclathrin-coatedtrafﬁckingintermediates
(15).IsoformaistheonlyformofOCRL1inbrain,whileinother
tissues both forms are expressed, suggesting that clathrin binding
is importantforOCRL1inthebrain.Totestthis hypothesis inthe
context of embryonic development, and to gain a better mechan-
istic explanation for the phenotypes we observe, rescue experi-
ments were performed using mutant OCRL1 lacking the LIDLE
motif. As shown in Fig 8A, the △LIDLE construct was unable
to rescue the mutant phenotype at the morphological level. In
fact, in  30% of embryos, the reduction in brain size was more
severe than in the mutant embryos alone. The △LIDLE mutant
was also compromised in its ability to rescue the increased apop-
tosis and reduced proliferation seen in the mutant embryos
(Figs 8B and C). To further assess the signiﬁcance of clathrin
bindingandOCRL1splicing,rescueexperimentswereperformed
with the b isoform of OCRL1. This construct failed to efﬁciently
rescuethemorphological,apoptosisandproliferationdefectsseen
in the mutant, conﬁrming the importance of clathrin binding
(Fig.8A–C).Together,ourresultsindicatethat5-phosphataseac-
tivityandinteractionwithclathrinareimportantforOCRL1func-
tion during embryonic brain development.
DISCUSSION
In this study, we report for the ﬁrst time, a zebraﬁsh model for
Lowe syndrome. This model recapitulates several of the
neurological features of Lowe syndrome including increased
susceptibility to heat-induced seizures and white matter
lesions. Attempts to generate a mouse model for studying
the neurological component of Lowe syndrome have so far
failed, most likely due to compensation of OCRL1 by
murine INPP5B (30), which is spliced differently in this or-
ganism to other vertebrates (42). Although zebraﬁsh expresses
INPP5B, it is unable to compensate for the loss of OCRL1 in
the neurological tissue, as seen for human Lowe syndrome
patients. Zebraﬁsh OCRL1 and INPP5B are highly conserved
with their human counterparts in terms of sequence identity
and domain organization. Moreover, zebraﬁsh OCRL1 has
the same subcellular localization as the human protein, and
is identical in its tissue-speciﬁc expression and splicing. To-
gether, these observations indicate that zebraﬁsh is a good
model to investigate the disease mechanisms of Lowe syn-
drome. In further support of this assertion, we observe a
1.8-fold increase in PtdIns(4,5)P2 levels in OCRL1-deﬁcient
zebraﬁsh embryos, which is similar to the increase seen in
cells derived from Lowe syndrome patients (39,40). Such an
increase in PtdIns(4,5)P2 levels indicates that despite the pres-
ence of numerous 5-phosphatase enzymes in vertebrates,
OCRL1 contributes a signiﬁcant proportion of total
5-phosphatase activity.
Several of the neurological defects in Lowe syndrome
patients are evident at birth, suggesting a developmental role
for OCRL1 within the central nervous system (1,2). Using
the zebraﬁsh model, we can now demonstrate that this is
indeed the case. The most striking developmental defect is
reduction in the size of the brain and eyes when observed at
1 dpf. This phenotype is speciﬁc: it is observed with both mor-
phant and mutant embryos that are deﬁcient in OCRL1, and it
is rescued by re-expression of WT OCRL1. Importantly, the
mutant/morphant phenotype is not due to a general develop-
mental delay, as assessed by somite number and gross morph-
ology. The morphological changes we observe therefore
reﬂect a more speciﬁc defect in the development of the
brain and eyes, tissues in which OCRL1 is particularly abun-
dant. Defective neural development likely accounts for the
impaired functionality of the brain that is observed in
OCRL1 mutants, namely increased susceptibility to
heat-induced seizures, which is evident already at 6 dpf.
This mimics the situation in Lowe syndrome, where increased
febrile seizures are seen in young and older patients alike
(2,34). Whether seizures account for the 3-fold higher mortal-
ity of juvenile OCRL1 mutant embryos is hard to say, but it is
interesting to note that epileptic seizures are a frequent cause
of death in Lowe syndrome patients (2). Those mutant zebra-
ﬁsh that do survive through to adulthood have a brain size
comparable with controls, as assessed by mMRI imaging.
However, in all mutant embryos, we observed periventricular
lesions in the brain, consistent with impaired functionality of
this organ. These lesions may be a long-term consequence
of defects occurring during development of the neural tissue,
resulting in suboptimal organization of neuronal networks,
which in the longer term causes increased cumulative neuronal
death. Alternatively, neuronal death in adults may arise
through defects intrinsic to the neurons themselves. This
could occur through defective clathrin-mediated trafﬁcking
that is important not only for synaptic vesicle recycling but
also receptor localization and responsiveness of post-synaptic
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ses PtdIns(3,4)P2, is important for NMDA receptor localiza-
tion and suppression of excitotoxic cell death (43). OCRL1,
by regulating endocytic trafﬁc, may also participate in this
process.
We observe reduced Akt signalling and increased apoptosis
in the OCRL1-deﬁcient mutants. This indicates that OCRL1 is
important for signalling through the Akt pathway. Conceiv-
ably, OCRL1 could directly regulate Akt through hydrolysis
of PtdIns(3,4,5)P3, which binds Akt to promote membrane re-
cruitment and activation. It could also regulate Akt through
altering levels of PtdIns(4,5)P2, the precursor of
PtdIns(3,4,5)P3. However, we believe that these possibilities
are unlikely as OCRL1 hydrolyses PtdIns(4,5)P2 and
PtdIns(3,4,5)P3, and so any loss of activity would be expected
to increase Akt activation, which is contrary to what we see.
Another possibility is that OCRL1 regulates Akt through its
association with the endosomal scaffolding protein APPL1,
which is important for Akt signalling from endosomes.
Indeed, MO-induced knockdown of APPL1 in zebraﬁsh
leads to increased apoptosis in the nervous system (44).
However, proliferation is unaffected in APPL1 morphants, in-
dicating that the mechanisms underlying the neurological
defects we observe are not the same as those in APPL1
Figure 8. Catalytic activity and binding to clathrin are required for OCRL1 function in brain development. (A) Representative bright ﬁeld images of 26 hpf
OCRL12/2 mutant embryos either uninjected (left) or injected with mRNA encoding GFP–OCRL1 D480A (right). The phenotypes were scored as dysmorphic
(left) or severely dysmorphic (right), in which the brain size is further reduced when compared with the mutant alone. Quantitation of the morphological phe-
notypes obtained upon expression of the indicated constructs in OCRL12/2 mutant embryos. Results are expressed as the mean + SEM (n ¼ 38–324 embryos
from 2 to 18 experiments). (B) Representative AO staining of apoptosis in OCRL12/2 mutant embryos expressing GFP–OCRL1 D480A or GFP–OCRL1
△LIDLE. Note the increased apoptosis in the head region (left) and spinal cord (right), indicated by arrows. Quantitation of the AO staining obtained upon
expression of the indicated constructs in OCRL12/2 mutant embryos. Results are expressed as the mean + SEM (n ¼ 29–136 embryos from 2 to 17 experi-
ments). (C) Quantitation of proliferation as assessed by PH3 staining upon expression of the indicated constructs in OCRL12/2 mutant embryos. Results are
expressed as the mean + SEM (n ¼ 13–89 embryos from 2 to 12 experiments).
Figure 7. Decreased Akt signalling, cell survival and proliferation in OCRL1-deﬁcient embryos. (A) Top: western blotting of 1–4 dpf WT and OCRL12/2
embryo extracts with the indicated antibodies. Representative blots and quantitation are shown. Results are expressed as the mean + SEM from ﬁve experiments.
∗P , 0.01. (A) Bottom: Extracts from 1 dpf WT, OCRL12/2 embryos or OCRL12/2 embryos expressing GFP–OCRL1 isoform a were analysed by western
blotting with the indicated antibodies. Quantitation from two experiments is shown, with error bars indicating the range of values obtained. (B) WT, OCRL12/2
and OCRL1 2/2 embryos expressing GFP–OCRL1 isoform a at 28 hpf were labelled with acridine orange (AO) to label apoptotic cells. Embryos with different
levels of apoptosis were divided into four categories as indicated: from + to ++++. Embryos in each category were counted and data are presented as the
mean + SEM (n ¼ 37–96 embryos from 3 to 12 experiments). (C) WT, OCRL12/2 and OCRL1 2/2 embryos expressing GFP–OCRL1 isoform a at
28 hpf were stained with anti-phosphohistone H3 (PH3) to label mitotic cells. Note the abundance of mitotic cells in the head region, where they align next
to the ventricle boundary (arrows). Embryos were scored as having normal staining indicating WT levels of proliferation (+) or weak staining indicating
clearly reduced proliferation (–). Embryos in each category were counted and data are presented as the mean + SEM (n ¼ 35–89 embryos from 4 to 12 experi-
ments).
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OCRL1, and the signiﬁcance of OCRL1 binding for APPL1
function in signalling is so far unclear (7). We cannot
exclude the possibility that OCRL1 participates in APPL1-
mediated Akt signalling, but our data are more consistent
with reduced Akt signalling arising from defects in membrane
trafﬁc. OCRL1 lacking the LIDLE clathrin-binding site, which
is required for OCRL1 incorporation into clathrin-coated traf-
ﬁcking intermediates (15), fails to rescue apoptosis in the
mutant. A similar result is seen with the isoform b of
OCRL1, in which the LIDLE motif is inaccessible for clathrin-
binding. This indicates that OCRL1 functions in the context of
clathrin-mediated trafﬁcking to promote Akt signalling.
Neurotrophin receptors, which play a key role in neuronal
survival, differentiation and proliferation, are internalized in
a clathrin-dependent manner and delivered to endosomes.
Cell survival signalling requires retrograde trafﬁcking of neu-
rotrophin receptor-containing endosomes (45). Interestingly, it
has recently been shown that regulated actin disassembly on
endosomes is required to promote endosomal maturation and
survival signalling (46). Loss of OCRL1 causes increased
PtdIns(4,5)P2 levels on endosomes, which results in the accu-
mulation of actin and perturbation of endocytic trafﬁcking
(23). OCRL1 could therefore regulate Akt signalling in
neurons by promoting endosomal actin disassembly to
promote retrograde movement of neurotrophin receptor-
containing endosomes. Of course, defective endocytic trafﬁck-
ing is likely to impact upon other signalling pathways active
during neuronal development that may contribute to the phe-
notypes we observe upon depletion of OCRL1. Indeed, it
has been demonstrated that OCRL1 regulates trafﬁcking to
the cilium, which is important for ciliogenesis (47). Defects
in this pathway, which is independent of clathrin binding,
are likely to contribute to defective signalling through
primary cilia (47). Thus, OCRL1 is likely to regulate multiple
trafﬁcking routes that in turn inﬂuence several developmental
signalling pathways. Our ﬁndings strongly suggest that a sig-
niﬁcant component of the neurological dysfunction seen in
Lowe syndrome is due to defective clathrin-mediated trafﬁck-
ing of receptors.
Akt signalling is important for several cellular processes in
addition to cell survival. Among these include proliferation
and cell migration. The reduced Akt signalling in OCRL1-
deﬁcient embryos could therefore account for the reduction in
proliferation we observe, as could perturbation of other signal-
lingpathways.Another possibility isthatdefectivecelldivision
plays a role. OCRL1 was recently shown to participate in cyto-
kinesis (10,25), suggesting that impairment of this process
during embryogenesis could contribute to the phenotype we
observe. This may be the case, but it should be noted that
during the early stages of embryogenesis, e.g. up to and includ-
inggastrulation,weseenoapparentdefectincelldivisionperse
in the OCRL1-deﬁcient embryos (data not shown). Thus, the
extent to which a cytokinesis defect contributes to Lowe syn-
drome pathology remains unclear. We also failed to observe
defectsinconversionandextensionmovementsduringgastrula-
tion (data not shown), arguing against major defects in cell mi-
gration at this time. However, we cannot exclude the possibility
that cell migration, and in particular migration of neurons, is
affected at later stages in development.
In summary, we have developed a new animal model to in-
vestigate Lowe syndrome. This model recapitulates several of
the neurological features of Lowe syndrome. It has also
allowed us to identify a role for OCRL1 in maintaining Akt
signalling and cell survival during embryogenesis. We have
been able to demonstrate that OCRL1 function during devel-
opment is dependent upon its 5-phosphatase activity and
binding to the clathrin machinery. Together, our results
support a role for OCRL1 in maintaining developmental sig-
nalling pathways downstream of clathrin-mediated membrane
trafﬁc. The zebraﬁsh model should prove useful in further dis-
secting the disease mechanisms of Lowe syndrome, not just
within the central nervous system but also in the other affected
tissues.
MATERIALS AND METHODS
Antibodies
Polyclonal antibodies to zebraﬁsh OCRL1 were raised in
sheep using GST-tagged N-terminus (amino acids 1–303)
and afﬁnity puriﬁed using His-tagged N-terminus OCRL1 co-
valently coupled to CNBr beads. Other polyclonal antibodies
were sheep anti-Golgi-84 (48), goat anti-EEA1 (Santa Cruz
Biotechnology), mouse anti-clathrin X22 (Liz Smythe, Uni-
versity of Shefﬁeld, UK), mouse anti tubulin TAT-1 (Keith
Gull, University of Oxford, UK), mouse acetylated tubulin
(Sigma T7451), rabbit anti-PH3 Ser10 (Upstate 06570),
rabbit GFAP (DAKO Z0334), rabbit pAkt (pSer473, Cell Sig-
nalling 4060S), rabbit Total Akt (Cell Signalling 9272), mouse
pERK (Cell Signalling 9106S), mouse Total ERK (Cell Sig-
nalling 4696). Fluorophore Alexa594, Alexa488, cy3 and
cy5) and horseradish peroxidase-conjugated secondary anti-
bodies were purchased from Molecular Probes, Tago Immuno-
logicals or Invitrogen.
Molecular biology
All constructs were made using standard molecular biology
techniques. Full-length D. rerio OCRLb cDNA was obtained
from the MRC Geneservice as IMAGE clone 2600692.
A two-step mutagenesis insertion of the sequence GGA
GAGGATAGCTGCATGGAAAAG was performed to make
D. rerio OCRLa. Full-length OCRL1 isoforms a and b were
cloned into a modiﬁed pcGlobin vector for N-terminal
tagging with GFP, expression in tissue culture cells and in
vitro synthesis of mRNA. Point mutations were introduced
by PCR using the site-directed mutagenesis Quickchange
method (Stratagene). An N-terminal fragment of OCRL1 en-
coding amino acids 1–303 was cloned into pGEX 4T-1
vector for bacterial expression of protein and antibody produc-
tion. Fragments of OCRL (1–608 bp and 1765–2392 bp) were
cloned into pCR + BluntII-TOPO (Invitrogen) for generation
of ISH probes. DIG probes were generated with the DIG
RNA labelling kit (SP6/T7, Roche) according to the manufac-
turer’s instructions. Primer sequences for all manipulations are
available upon request. All constructs were veriﬁed by DNA
sequencing using the ABI PRISM Big dye Terminator TM
Kit version 2 (PE Applied Biosystems). Plasmid encoding
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vided by Dr Stephen Royle (University of Liverpool, UK).
Zebraﬁsh strains and husbandry
Zebraﬁsh were raised and maintained at the University of
Manchester Biological Services Unit as described (49).
OCRL+/2 F2 families were obtained from Znomics Inc.
Inbreeding generated F3 embryos for genotyping. Further
inbreeding generated F4–F6 embryos for analysis. All
animal procedures were subject to local ethical review and
performed under a Home Ofﬁce license.
RNA isolation, RT–PCR and genomic DNA isolation for
genotyping
Total RNA was isolated from zebraﬁsh larvae using Trizol
(Invitrogen) and reverse-transcribed with Superscript First
Strand (Invitrogen) to produce cDNA. For direct visualization
of ampliﬁcation products, cDNA was ampliﬁed using standard
PCR conditions and appropriate primer pairs. For genotyping,
genomic DNA was isolated by a HotSHOT DNA extraction
procedure. Brieﬂy, a tail clip was deposited into 100 ml
50 mM NaOH and heated for 20 min at 958C. After cooling
to 48C, 10 ml1M Tris pH 8.0 was added and clariﬁed by cen-
trifugation and stored at 2208C.
In situ hybridization
Embryos were dechorionated by pronase (Roche) and ﬁxed in
4% buffered paraformaldehyde (PFA/PBS) overnight at 48C.
They were then washed three times in PBS containing 0.1%
Triton X-100 (PBST) prior to being dehydrated in methanol
at 2208C for at least 30 min. Embryos were rehydrated in des-
cending concentrations of methanol in PBST solution.
Embryos were treated with 10 mg/ml protease K (Sigma) for
15 min. After rinsing twice in 2 mg/ml glycine/PBST,
embryos were ﬁxed in 4% PFA/PBS for 20 min. Embryos
were washed ﬁve times for 5 min in PBST solution and then
brieﬂy washed in 50% PBST/50% hybridization buffer,
before incubating them in hybridization buffer for 1 h at
658C. Hybridization was performed at 658C overnight in hy-
bridization buffer: 50% formamide, 5x saline-sodium citrate
buffer (SSC), 0.5 mg/ml Torula yeast RNA (Sigma), 50 mg/
ml Heparin, 0.1% Tween20 and 9 mM citric acid monohydrate
pH 6.0–6.5 containing the DIG probe. Embryos were washed
three times for 5 min in 50% hybridization buffer/50% 2x SSC
at 658C and then washed in descending concentrations of SSC
in 0.1% Tween-20 solution at 658C. Embryos were washed in
descending concentration of 0.2x SSC in PBST solution.
Embryos were blocked for 1 h in 5% fetal calf serum (FCS)
in 10 mg/ml bovine serum albumin (BSA)/PBST prior to incu-
bating them with anti-DIG-AP antibody (Roche) in 2 mg/ml
BSA/PBST at 48C overnight. After washing eight times in
PBST, embryos were equilibrated in staining buffer (100 mM
NaCl, 100 mM Tris–HCl, pH 9.5, 50 mM MgCl2, 0.1%
Triton X-100). For colour reaction, nitro blue terazolium/5-
bromo-4-chloro-3-indolyl phosphate was used in staining
buffer. Whole embryos were imaged on a Leica MZ6 stereo-
microcope after ﬁxing in either PFA or methanol, mounted
in glycerol or benzyl alcohol/benzyl benzoate (BBA). For
cryosections, embryos were embedded in gelatin solution
(15% ﬁsh skin gelatin, 15% sucrose) overnight and frozen
on dry ice for 30 min. The sections were cut at 30 mm thick-
ness using a Leica cryostat, placed on SuperFrost Plus slides
and kept at 2808C for at least 1 h. Slides were removed
from 2808C and dried for 1 h, washed for 2 min in acetone,
rehydrated for 1 min in PBS and mounted using Mowiol. Sec-
tions were imaged using Nikon Eclipse 80i microscope and
processed using Photoshop CS2.
Cell culture and immunoﬂuoresence microscopy
AB9 cells were grown at 288C and 5% CO2 in Dulbecco’s
modiﬁed Eagle medium supplemented with 15% FCS and
Penicillin/Streptomycin. PAC2 cells were grown at 288Ci n
L-15 medium containing 15% FCS and Penicillin/Strepto-
mycin. Transient transfections were performed using Fugene
HD (Roche Biochemicals, Indianapolis, IN, USA) according
to the manufacturer’s instructions using 2 mg DNA, 5 mg
Fugene HD in 100 ml OptiMEM. Immunoﬂuorescence micros-
copy was performed according to Choudhury and co-workers
(14). Images were analysed using an Olympus BX60 upright
microscope equipped with a MicroMax cooled, slow-scan
charge-coupled device camera (Roper Scientiﬁc, Sarasota,
FL, USA) driven by Metaview software (University Imaging
Corporation, Sunnyvale, CA, USA). Images were processed
using Adobe Photoshop CS5.
RNA expression and morpholino injections in zebraﬁsh
Capped mRNA encoding GFP–OCRL1 constructs was tran-
scribed using the T7 mMessage mMachine kit (Ambion) and
approximately 1 nl of a 0.4–1.0 mg/ml stock was injected
into one-cell stage mutant embryos using a PLI-90
Pico-Injector (Harvard Apparatus). MO-modiﬁed antisense
oligonucleotides targeting OCRL (ATGMO: AATCCCAA
ATGAAGGTTCCATCATG) as well as a standard control
MO (CCTCTTACCTCAGTTACAATTTATA) were obtained
from GeneTools and 4–6 ng was injected into one-cell stage
embryos.
Magnetic resonance imaging
Adult zebraﬁsh at 1 year of age were euthanized and were
ﬁxed in 4% PFA/PBS for 2 days and subsequently embedded
in Fomblin. Micro-MRI imaging was performed according to
Haud et al.( 50).
Immunohistochemistry
Adult zebraﬁsh previously ﬁxed in 4% PFA/PBS and analysed
by mMRI were embedded in parafﬁn and 5 mm sections cut.
The primary antibody was mouse anti-GFAP (1:300), incu-
bated overnight at 48C. The secondary antibody used was Vec-
tastain biotinylated horse anti-pan-Ig antibody. Following
incubation with secondary antibody, the sections were incu-
bated with the ABC kit (Vectorlabs) and stained with DAB
(Vectorlabs) before mounting with Pertex. Images were col-
lected using a Zeiss Axioplan microscope and captured
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(Zeiss). Images were then processed and analysed using Axio-
vision software (Zeiss), Photoshop CS5 and ImageJ.
Time-lapse microscopy
Zebraﬁsh embryos were collected 20 min post fertilization and
placed in wells made of 0.7% agarose in chorion water (Instant
Ocean). The embryos were incubated at 288C and imaged
using a Nikon TE2000 PFS microscope and Cascade II
EMCCD camera with a dedicated manufacturer’s software.
Embryos were imaged every 5 min for 24 h. The images
were processed using ImageJ software.
Protein extraction and western blotting
Embryos were dechorionated by pronase and deyolked in
Ginzburg buffer with protease inhibitor cocktail as described
in the zebraﬁsh book (49). Embryos were either extracted in
native or denaturing conditions. For native conditions,
buffer containing 1 mM Hepes, pH 7.4, 1 mM ethylene
diamminetetraacetic acid, 15 mM NaCl2, 0.5% Triton X-100,
Protease Inhibitor Cocktail III (Calbiochem) and 20 mM
b-glycerophosphate was used. Homogenization was per-
formed for 2 min on ice with an Ultra-Turrax T8 (Ika-Werke),
followed by 5 min incubation on ice. Supernatants were clari-
ﬁed by centrifugation at 20000 g for 5 min in a microfuge at
48C. For denaturing conditions, embryos were homogenized in
the 20 mM Hepes, pH 7.4, 0.1 M NaCl, 1 mM dithiothreitol
(DTT) buffer containing 1% sodium dodecylsulphate (SDS)
with an Ultra-Turrax for 2 min on ice, then boiled for 3 min
and an equal volume of 20 mM Hepes, pH 7.4, 0.1 M NaCl,
1m M DTT buffer containing 4% Triton X-100 was added
and re-homogenized for another 2 min on ice. Extracts were
clariﬁed in a microfuge. Adult tissues were extracted and im-
mediately snap-frozen in liquid nitrogen. Proteins were
extracted using the native extraction protocol. Protein was
determined using the bicinchoninic acid method (Pierce)
according to manufacturer’s instructions and snap-frozen and
stored at 2808C. Samples were boiled with SDS sample
buffer prior to sodium dodecylsulphate–polyacrylamide gel
electrophoresis and western blotting.
Apoptosis and proliferation analysis
Zebraﬁsh embryos at 24 hpf were stained with 5 mg/ml of Ac-
ridine Orange (Sigma) in embryo water for 30 min, and then
washed three times for 5 min in embryo water. After anaesthe-
sia with Tricaine (Sigma), AO staining was visualized using a
Zeiss stereo Lumar V12 ﬂuorescent microscope ﬁtted with
ﬁlter set Lumar 38 and images were acquired using an
AxioCam MRm camera and processed using AxioVision soft-
ware version 4.8 (Image Associates). TUNEL was performed
with ApopTag Red in situ Apoptosis Detection Kit (Chemi-
con) according to the manufacturer’s instructions. To
analyse proliferation, whole-mount immunoﬂuorescence was
performed with anti-phospho Histone H3 antibodies. Brieﬂy,
dechorionated embryos were ﬁxed in 4% PFA/PBS at 48C
overnight. Embryos were washed three times in methanol,
and were rehydrated in descending concentrations of methanol
in PBST solution. Primary antibody was incubated overnight
at 48C in 10% FBS/PBST. After six washes of 20 min in
PBST, embryos were incubated in ﬂuorescently tagged sec-
ondary antibody overnight at 48C. After three washes of
15 min, embryos were imaged using the Zeiss stereo Lumar
V12 ﬂuorescent microscope.
Lipid analysis
Zebraﬁsh embryos at 48 hpf (60–80 embryos per labelling)
were labelled in 500 ml chorion water (Instant Ocean) contain-
ing 300 mCi/ml
32P-orthophosphate for 2 h at 288C. Thereafter,
the ﬁsh were pelleted and total lipids were extracted using
500 ml of methanol, 200 ml of 2.4 M hydrochloric acid and
250 ml of chloroform and a Bioruptor Sonicator set at
maximum amplitude for 2.5 min at room temperature. Phase
separation was achieved by the addition of 250 ml of chloro-
form and 250 ml of milliQ water. Fifty micrograms of
Folsch-extracted cow brain lipids (Sigma) was added to all
samples to aid recovery of phosphoinositides. After centrifuga-
tion (20 000g, 5 min at room temperature), the upper phase was
removed and replaced with theoretical upper phase. The
samples were mixed, centrifuged and the lower phase was
recovered into a new Eppendorf tube. The samples were
dried in a vacuum centrifugal concentrator and then applied
to a thin layer chromatography (TLC) plate for development
once in the solvent mixture: chloroform/methanol/water/25%
ammonia solution (45/35/8/2 v/v/v/v). After drying, radioactiv-
ity within the PtdIns(4,5)P2 spot on the TLC plate was detected
by phosphorimaging (PharosFX Plus with ImageOne software,
BioRad). Conﬁrmation that the spot on the TLC plate was
PtdIns(4,5)P2 was addressed by high-performance liquid chro-
matography (HPLC) analysis in parallel samples. Total lipids
were ﬁrst deacylated prior to HPLC analysis according to
Jones et al.( 51).
Seizure analysis
Electrophysiological recordings of 6–7 dpf embryos were
made from the forebrain according to Baraban et al.( 52).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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